Meet our speakers

» Dr Jeremy Barton,

Vice President Oncology R&D, Biogen Idec

» Dr Margaret Beer,

Senior Director and Head of Licensing and External Research, Merck & Co

» Prof Jonas Bergh,

Muriel Edith Rickman Chair in Breast Oncology, University of Manchester; Scientific Director Oncology, Karolinska University Hospital; Scientific Advisory Group on Oncology, Committee for Medicinal Products for Human Use, EMEA

» Prof Rolf Bjerkvig,

Scientific Director, Norlux-Neuro Oncology

» Peter Collins,

Vice President Pharma Business Development, QIAGEN

» Ruggero Della Bitta,

Senior Vice President Oncology, Merck Serono

» Dr Jens Oliver Funk,

Senior Vice President R&D, Global Head Therapeutic Area Oncology, Merck Serono

» Dr Gilles Gallant,

Vice President Clinical Oncology, Human Genome Sciences

» Jean-Jacques Garaud,

Head of Pharma Research and Early Development, Roche

» Dr Liliane Goetsch,

Head of Experimental Oncology Department, Institute de Recherche Pierre Fabre

» Professor, Dr Michel Goldman,

Executive Director, Innovative Medicines Initiative

» Darren Hodgson,

Principal Scientist, AstraZeneca

» Dr. Lars Knoch,

Scientific Consultant Targeted Genome Editing EMEA , Sigma-Aldrich

» Dr Margaret Lee,

Vice President Therapeutic Area Research, Zalicus Inc (formerly CombinatoRx)

» Dr Nicolò Manaresi,

Chief Technology Officer, Silicon Biosystems

» Dr Patrick Matthias,

Senior Group Leader, Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation)

» Robert McCormack,

Vice President Scientific and Medical Affairs, Veridex (a Johnson & Johnson compnay)

» Stafford O'Kelly,

President Molecular Diagnostics, Abbott Molecular

» Dr David Perry,

Vice President Global Clinical and Medical Affairs, Baxter BioScience

» Dr Yuri Rukazenkov,

Global Brand Physician, AstraZeneca Pharmaceuticals

» Dr Hakan Sakul,

Senior Director and Global Head of Diagnostics, Pfizer Global R&D

» Dr Ralph Schiess,

Chief Executive Officer and Co-Founder , ProteoMediX AG

» Dr Diane Seimetz,

Chief Scientific Officer and Executive Vice President, Fresenius Biotech GmbH

» Rita Theodotou,

Director, Global Oncology, Bayer Healthcare

» Dr. Karsten Witt,

Senior Vice President Pharmacuetical Operations, OSI Pharmaceuticals, a subsidary of Astellas

» Dr Hagop Youssoufian,

Chief Medical Officer & Senior Vice President Global Clincial Sciences, ImClone Systems, a wholly-owned subsidary of Eli Lilly & Co

» Myriam Zylberman,

Corporate Affairs Director, Eli Lilly France

sponsors:

sponsorship opportunities

Sponsoring Targeted Cancer
Therapy World Congress 2010

is a time and cost-effective opportunity to develop

existing and new business.

Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.

Target your market!

For details contact
Daniel Raines

› follow us! › tweet this!

conference details

Conference:

Day 1

September 21, 8:30am - 5:30pm

Day 2

September 22, 8:30am - 5:30pm

Day 3
September 23, 9am - 5:30pm